Odanacatib Explained

Odanacatib (INN;[1] codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis.[2] It is an inhibitor of cathepsin K,[3] an enzyme involved in bone resorption.

The drug was developed by Merck & Co. The phase III clinical trial for this medicine was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015.[4]

In 2016, Merck discontinued development of odanacatib and announced it would not seek regulatory approval after analysis discovered an increased risk of stroke.[5]

This drug was developed at Merck Frosst in Montreal.

Notes and References

  1. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 60 . WHO Drug Information . 33 . 3 . 2008 . https://web.archive.org/web/20131026150609/https://www.who.int/medicines/publications/druginformation/innlists/RL60.pdf . 26 October 2013 . World Health Organization. 11 November 2016. 239 .
  2. Le Gall C, Bonnelye E, Clézardin P . Cathepsin K inhibitors as treatment of bone metastasis . Current Opinion in Supportive and Palliative Care . 2 . 3 . 218–222 . September 2008 . 18685424 . 10.1097/SPC.0b013e32830baea9 . 5834581 .
  3. Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC . 6 . The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K . Bioorganic & Medicinal Chemistry Letters . 18 . 3 . 923–928 . February 2008 . 18226527 . 10.1016/j.bmcl.2007.12.047 .
  4. Web site: Pierson R . 15 September 2014 . Merck osteoporosis drug passes trial, but side effects hover . . https://web.archive.org/web/20210711172651/https://www.reuters.com/article/us-merck-osteoporosis-idUSKBN0HA1Y820140915 . 2021-07-11 . live .
  5. News: Merck Provides Update on Odanacatib Development Program . Business Wire . 2016-09-02 . 2016-09-30 . https://web.archive.org/web/20160903172200/http://www.businesswire.com/news/home/20160902005107/en/Merck-Update-Odanacatib-Development-Program . 2016-09-03 . live.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Odanacatib".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.